Coronavirus Vaccine Update With Paul Offit, MD
Coronavirus Vaccine Update With Paul Offit, MD
Paul A. Offit, MD of @ChildrensHospPhila returns to JAMA's Q&A series to provide an update on the emergence of COVID-19 variants and their implications for vaccine development, including the JNJ vaccine, scheduled for a @US_FDA VRBPAC hearing on February 26, 2021. (see http://tinyurl.com/3dxhym3v). Recorded February 11, 2021.• Earn Free CME credits by watching JAMA Livestreams and completing a brief questionnaire.
• Claim 0.5 credits for each video at https://ja.ma/covidqa
• Coronavirus Resource page from the JAMA Network: https://ja.ma/covidyt
• To watch all the #JAMALive Q&A's Visit: https://ja.ma/covidqaytpl
• Don't forget to hit subscribe or click https://ja.ma/subscribe
Topics discussed in this interview:
0:00 Introduction
0:24 Are we seeing natural and vaccine induced immunity?
3:32 mRNA Vaccine safety update
6:30 Variants and COVID vaccines
10:28 Variants - concerns
12:55 Broadly neutralizing vaccine for all variants
15:18 Preparing for a virulent COVID-19 variant
16:53 Johnson and Johnson vaccine
18:52 Who should get the JnJ vaccine?
20:32 Biologics License Application (BLA)
21:18 Vaccine platforms and variants
22:15 Adverse events
23:30 Anti-vaxxers and vaccine hesitancy
26:16 Sputnik and other international vaccine efforts
30:00 When will kids get a COVID vaccine?
32:44 Mandating vaccines
---------------------------------------------------------------------------------
For more from JAMA
• https://www.jama.com
• https://www.facebook.com/JAMAJournal
• https://www.twitter.com/JAMA_Current
• https://www.linkedin.com/company/jamanetwor
Follow the JAMA Network
• https://www.jamanetwork.com
• https://www.jamanetworkaudio.com
• https://www.facebook.com/JAMANetwork
• https://www.twitter.com/JAMANetwork
• https://www.instagram.com/JAMANetwork
• https://www.pinterest.com/JAMANetwork
=====================================================================
#JAMALive #Coronavirus #COVID19 #SARSCoV2 #Pandemic
Access Non-GMO, antigen-free, FDA-approved antiviral medication formulas used in Moderna's Spikevax.
VirusTC is a retail provider of concentrated FDA-approved antiviral medication formulas. VirusTC wholesale formulas are used in Moderna products. We sell FDA-approved formulas that are compatible with university medical plans, federal insurance coverage, and many major insurance providers. Our medications are part of tailored non-invasive cancer treatment plans available at a hospital in your region. VirusTC targets problems and provides care for the symptoms. Our products and services are used by Fred Hutch Cancer Center, John Hopkins, University Hospitals, the United States Military, and professional sports. During Operation Cancer Moonshot 2023, VirusTC products killed cancer cells, increased strength, and redeveloped muscles, tissue, and brain cells after cancer treatments.